Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer

被引：0
|
作者：
Paolo Peterlongo
Gisella Figlioli
Andrew J. Deans
Fergus J. Couch
机构：
[1] IFOM – The FIRC Institute for Molecular Oncology,Genome Diagnostics Program
[2] St Vincent’s Institute,Genome Stability Unit
[3] Fitzroy,Departments of Health Sciences Research
[4] Laboratory Medicine and Pathology,undefined
[5] and Oncology,undefined
[6] Mayo Clinic,undefined
来源：
npj Breast Cancer | / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
FANCM protein truncating variants (PTVs) are emerging as risk factors for ER-negative and triple negative breast cancer. Here, we discuss evidence that greatest risk associates with PTVs, such as p.Arg658*, that extensively truncate the 2048 amino acid FANCM protein. Moreover, risks associated with other less-truncating FANCM PTVs such as p.Gln1701* and p.Gly1906Alafs12* may be amplified by additional gene variants acting as modifiers. Further studies need to be conducted taking into considerations these aspects.
引用
收藏
相关论文
共 50 条
  • [41] Hyperactive MAPK dysregulation of microRNAs contributes to the ER-negative phenotype in breast cancer
    Philip, Miller C.
    Lairet, Stephania
    Clarke, Jennifer
    Richer, Jennifer
    El-Ashry, Dorraya
    CANCER RESEARCH, 2012, 72
  • [42] EphA2 overexpression in ER-negative metastatic breast cancer cells
    Erzinger, Stephanie A.
    Liu, Hui
    Kiriakova, Galina
    Price, Janet E.
    CLINICAL & EXPERIMENTAL METASTASIS, 2011, 28 (02) : 219 - 219
  • [43] Bioinformatics Analysis in the Identification of Prognostic Signatures for ER-Negative Breast Cancer Data
    Divya, P.
    Suresh, S.
    JOURNAL OF THE INDIAN SOCIETY FOR PROBABILITY AND STATISTICS, 2024, 25 (01) : 1 - 16
  • [44] Interleukin-8 in progression of ER-positive and ER-negative breast cancer patients
    Todorovic-Rakovic, N.
    Milovanovic, J.
    Abu Rabi, Z.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S115 - S115
  • [45] ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches
    Chen, Jin-Qiang
    Russo, Jose
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1796 (02): : 162 - 175
  • [46] Significant ERβ mRNA expression in ERα-negative and triple negative breast cancers
    Choi, Y.
    Kim, H.
    Kim, T.
    HISTOPATHOLOGY, 2012, 61 : 16 - 16
  • [47] Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer
    Switzer, Christopher H.
    Glynn, Sharon A.
    Ridnour, Lisa A.
    Cheng, Robert Y. -S.
    Vitek, Michael P.
    Ambs, Stefan
    Wink, David A.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (11) : 644 - 651
  • [48] Population-based survival-cure analysis of ER-negative breast cancer
    Lan Huang
    Karen A. Johnson
    Angela B. Mariotto
    James J. Dignam
    Eric J. Feuer
    Breast Cancer Research and Treatment, 2010, 123 : 257 - 264
  • [49] Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer
    Parl, FF
    PHARMACOGENOMICS JOURNAL, 2003, 3 (05): : 251 - 253
  • [50] Novel role of DAPK-1 in growth regulation of ER-negative breast cancer
    Zhao, Jing
    Zhang, Yun
    Hill, Jamal
    Speers, Corey
    Mazumdar, Abhijit
    Mills, Gordon
    Browns, Powel
    CANCER RESEARCH, 2012, 72
12345